Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lutetium-177 PSMA-R2

Next Previous
X
Search
Drug Profile

Lutetium-177 PSMA-R2

Alternative Names: 177Lu-PSMA-R2; Lu177-PSMA-R2

Latest Information Update: 11 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Johns Hopkins University
  • Developer Advanced Accelerator Applications
  • Class Antineoplastics; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 06 Jul 2022 Advanced Accelerator Applications terminates a I/II trial in Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in United Kingdom, USA as per sponsor's decision (NCT03490838) (EudraCT-2017-004034-29)
  • 26 Oct 2021 Discontinued - Phase-I/II for Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in Spain, United Kingdom, USA (IV)
  • 17 Mar 2021 Phase I/II trial is still ongoing in Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in Spain, United Kingdom, USA (NCT03490838) (EudraCT-2017-004034-29)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top